Added to YB: 2026-08-11
Pitch date: 2026-08-09
NVO [neutral]
Novo Nordisk A/S
+1.55%
current return
Author Info
Kontra Invest is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 47.00
Price Target
N/A
Dividend
3.83%
EV/EBITDA
8.24
P/E
11.65
EV/Sales
4.39
Sector
Pharmaceuticals
Category
growth
Novo Nordisk after Q2 ($NVO $LLY): There are reasons to be more constructive
NVO (earnings): Q2 beat flattered by ~DKK2B gross-to-net adj, but guidance raised (sales/op profit growth to 0% to -6% from -4% to -12%). Oral Wegovy scaling fast: 1.5M patients, 90% US oral share, 80% GLP-1 naïve (expands market). UK launch wild: 300K patients in 3wks. Risks: pricing pressure, semaglutide LoE, Lilly, weak FCF. Constructive—2027 debate is whether new portfolio outgrows old decline.
Read full article (8 min)